Forging a Breakthrough Platform for In Vivo Cell and Gene Therapy

Interius is developing new ways to engineer cells inside the human body, right where they live

join us

Targeted gene delivery

Right Cell, Right Payload, Right Disease

Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.


Core Technologies Enable In Situ Re‑engineering of Cellular Functions

Our lead programs are initially focused on treating hematologic malignancies by leveraging the Interius platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments.

We are also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.

Based on innovations conceived at Interius, we can now rethink how genetic medicine can be used to create transformational therapies for our patients.

Phil Johnson, CEO


Join Us on Our Fantastic Voyage

We are looking for passionate folks who want to make a difference in the world. Talent matters, but so does decorum and compassion. Come join us and become an Interian.


see our open positions